Putative Roles for PI3K α and δ Isoforms in Refractory Mantle Cell Lymphoma

Publisher： Karger

E-ISSN： 1421-9662|131|4|218-219

ISSN： 0001-5792

Source： Acta Haematologica, Vol.131, Iss.4, 2013-11, pp. : 218-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 55-65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 224-235

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activation of PI3K Is Associated with Reduced Survival in Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 80, Iss. 4, 2008-06 ,pp. : 372-377

Karger

Access to resources Recommend Favorite

Class IA Phosphatidylinositol 3-Kinase Inhibition Inhibits Cell Growth and Proliferation in Mantle Cell Lymphoma

By  

Acta Haematologica, Vol. 131, Iss. 1, 2013-09 ,pp. : 59-69

Karger

Access to resources Recommend Favorite

Involved‐field radiotherapy for patients with mantle cell lymphoma

By  

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, Vol. 59, Iss. 5, 2015-10 ,pp. : 631-639

John Wiley & Sons Inc

Access to resources Recommend Favorite